Tubulin · PROTEIN COMPLEX GROUP · Trichophyton
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Tubulin shows approved-linked disease relevance led by candidiasis. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt F2SZD3. Start with candidiasis, then reuse UniProt F2SZD3 as the stable protein anchor across project notes and exports.
Start with candidiasis, then reuse UniProt F2SZD3 as the stable protein anchor across project notes and exports.
Tubulin shows approved-linked disease relevance led by candidiasis. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with candidiasis because it currently carries approved-linked support. Linked drugs include GRISEOFULVIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTubulin beta chain
Review this target as Tubulin, mapped to UniProt F2SZD3. ChEMBL maps the protein component as Tubulin beta chain. Sequence length is 449 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tubulin as ChEMBL target CHEMBL2364703, mapped to UniProt F2SZD3. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Tubulin is the right protein anchor across sources, using UniProt F2SZD3 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why candidiasis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Tubulin |
| Target Type | PROTEIN COMPLEX GROUP |
| Organism | Trichophyton |
| UniProt | F2SZD3 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Tubulin beta chain |
| UniProt Accession | F2SZD3 |
| Component Type | Protein |
| Sequence Length | 449 aa |
Tubulin beta chain
Review this target as Tubulin, mapped to UniProt F2SZD3. ChEMBL maps the protein component as Tubulin beta chain. Sequence length is 449 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Tubulin shows approved-linked disease relevance led by candidiasis. 4 more disease programs remain visible in the same review block.
Start review with candidiasis because it currently carries approved-linked support. Linked drugs include GRISEOFULVIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.